HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Chronic myeloid leukemia — Clinical Guidelines

Overview

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the BCR-ABL1 fusion gene, leading to uncontrolled proliferation of myeloid cells 5. It typically progresses through chronic, accelerated, and blast phases 2.

Diagnosis

Key Diagnostic Criteria: Presence of the Philadelphia chromosome (Ph) or BCR-ABL1 fusion gene 5.

Recommended Tests:

- Cytogenetic analysis for Ph chromosome 5. - Molecular testing for BCR-ABL1 transcript levels 5. - Complete blood count (CBC) showing elevated white blood cell count 33.

Grading:

- Based on cytogenetic response and molecular monitoring (e.g., major, minor, or no cytogenetic response) 2 33.

Management

First-Line Treatments:

- Tyrosine Kinase Inhibitors (TKIs): Imatinib (400-800 mg/day), Dasatinib (100 mg/day), Nilotinib (300-400 mg/day), Ponatinib (15-45 mg/day) 2 34.

Adjunctive Treatments:

- Erythropoietic-stimulating agents for imatinib-induced anemia 31. - Management of comorbidities and polypharmacy in elderly patients 27 29.

Treatment-Free Remission (TFR): Considered for patients with sustained deep molecular response (typically MR4.5) 15 23.

Special Populations

Pregnancy:

- TKIs are generally contraindicated due to potential adverse events; alternative management strategies may be necessary 1.

Pediatrics:

- Imatinib is effective but requires monitoring for growth deceleration 8.

Elderly:

- Comorbidities and polypharmacy can impact treatment response and toxicity; individualized management is crucial 27 29.

Comorbidities:

- Presence of conditions like IgA nephropathy may influence disease presentation 30.

Key Recommendations

Initiate TKI therapy with imatinib, dasatinib, or nilotinib based on patient-specific factors and resistance profiles (Evidence: Strong 2 34).

Monitor molecular response using BCR-ABL1 transcript levels to guide treatment adjustments (Evidence: Strong 2).

Consider treatment-free remission for patients achieving sustained deep molecular response (MR4.5) (Evidence: Moderate 15 23).

Carefully monitor pediatric patients for growth suppression while on TKI therapy (Evidence: Moderate 8).

Tailor treatment in elderly patients considering comorbidities and polypharmacy impacts (Evidence: Moderate 27 29).

References

1 Faisal MS, Rehman AU, Mohsin A, Mushtaq H, Rehman WU, Rehman MU et al.. Pregnancy-Related Adverse Events with Tyrosine Kinase Inhibitor Use in Chronic Myeloid Leukemia: A FAERS Pharmacovigilance Analysis (2001-2024). Clinical lymphoma, myeloma & leukemia 2026. link 2 Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H et al.. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia 2025. link 3 Shi Y, Deng L, Zhu J, Huang Y, Zeng M, Mao H et al.. BCR-ABL tyrosine kinase inhibitors associated acute kidney injury: a pharmacovigilance study based on the FAERS database with a case report. BMC nephrology 2025. link 4 Xia T, Shu B, Peng Y, Wang B. Post-marketing safety signals of imatinib: pharmacovigilance insights from the FDA Adverse Event Reporting System (FAERS) and implications for clinical practice. European journal of clinical pharmacology 2025. link 5 Wu A, Liu X, Fruhstorfer C, Jiang X. Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia. International journal of molecular sciences 2024. link 6 Zhao D, Long X, Wang J. Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System. Expert opinion on drug safety 2024. link 7 Liu Z, Wu D, Ke C, Nian Q, Chen Y, Huang Y et al.. Real-World Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System Database for Asciminib. Oncology 2024. link 8 Gupta P, Banothu KK, Haldar P, Gupta AK, Meena JP. Effect of Imatinib Mesylate on Growth in Pediatric Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis. Journal of pediatric hematology/oncology 2023. link 9 Singh AK, Kumar A, Agrawal N, Bhurani D, Ahmed R, Sharma M. Prevalence of Anemia among Chronic Myeloid Leukemia Patients Treated with Imatinib: A Evidence-based Meta-analysis. Current reviews in clinical and experimental pharmacology 2023. link 10 Iriyama N. Chronic myeloid leukemia: the cutting-edge evidence and things we should know. International journal of hematology 2023. link 11 Hewison A, Roman E, Smith A, McCaughan D, Sheridan R, Patmore R et al.. Chronic myeloid leukaemia: A qualitative interview study exploring disease impact from patient and practitioner perspectives. European journal of oncology nursing : the official journal of European Oncology Nursing Society 2023. link 12 Huang J, Cai J, Ye Q, Jiang Q, Lin H, Wu L. Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study. BMJ open 2023. link 13 Turki F, Louati N, Kamoun H, Keskes L, Rebaii T, Frikha R. Update meta-analysis from biomedical literature about MTHFR'polymorphisms and the CML' risk. La Tunisie medicale 2022. link 14 Yassin M, Al-Mashdali AF, Al-Dubai HN. Avascular necrosis in patients with chronic myeloid leukemia: A systematic review. Acta bio-medica : Atenei Parmensis 2022. link 15 Dengler J, Tesch H, Jentsch-Ullrich K, Gerhardt A, Schulte C, Lipke J et al.. Treatment-Free Remission in Real-World Chronic Myeloid Leukemia Patients: Insights from German Hematology Practices. Acta haematologica 2022. link 16 Yassin MA, Ata F, Mohamed SF, Alkhateeb A, Naeem U, Al-Qatami AI et al.. Ophthalmologic manifestations as the initial presentation of chronic myeloid leukemia: A review. Survey of ophthalmology 2022. link 17 Ali E, Soliman A, De Sanctis V, Nussbaumer D, Yassin M. Priapism in Patients with Chronic Myeloid Leukemia (CML): A Systematic Review. Acta bio-medica : Atenei Parmensis 2021. link 18 Heiney SP, Sorrell M, Sheng J, Adams SA, Nelson K, Nguyen LA et al.. Interventions to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review. American journal of clinical oncology 2021. link 19 Phukan A, Mandal PK, Dolai TK. Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India. Annals of hematology 2021. link 20 Strohbehn GW, Daugherty CK. Mistaking the Trees for the Forest?. The oncologist 2020. link 21 Caocci G, Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I et al.. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. Hematological oncology 2019. link 22 Flynn KE, Myers JM, D'Souza A, Schiffer CA, Thompson JE, Atallah E. Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. The oncologist 2019. link 23 Rea D, Ame S, Berger M, Cayuela JM, Charbonnier A, Coiteux V et al.. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group. Cancer 2018. link 24 Jiang Q, Yu L, Gale RP. Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia. Journal of cancer research and clinical oncology 2018. link 25 . Imatinib: muscle pain suggestive of a withdrawal syndrome. Prescrire international 2016. link 26 Roche-Lestienne C, Boudry-Labis E, Mozziconacci MJ. Cytogenetics in the management of "chronic myeloid leukemia": an update by the Groupe francophone de cytogénétique hématologique (GFCH). Annales de biologie clinique 2016. link 27 Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M et al.. Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Oncotarget 2016. link 28 Cortes J, Mauro M, Steegmann JL, Saglio G, Malhotra R, Ukropec JA et al.. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System. American journal of hematology 2015. link 29 Iurlo A, Ubertis A, Artuso S, Bucelli C, Radice T, Zappa M et al.. Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients. European journal of internal medicine 2014. link 30 Udani A, Vijayakumar M, Prahlad N, Ekambaram S. Chronic myeloid leukemia in a child with IgA nephropathy. Indian pediatrics 2012. link 31 Santos FP, Alvarado Y, Kantarjian H, Verma D, O'Brien S, Mattiuzzi G et al.. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer 2011. link 32 Kizaki M, Okamoto S, Tauchi T, Tanaka H, Tanimoto M, Inokuchi K et al.. Current and future perspectives on the TARGET system: the registration system for Glivec established by the JSH. International journal of hematology 2008. link 33 Gupta A, Prasad K. Hematological and molecular response evaluation of CML patients on imatinib. The Journal of the Association of Physicians of India 2007. link 34 Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ et al.. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007. link 35 Pavithran K, Thomas M. Chronic myeloid leukemia presenting as gout. Clinical rheumatology 2001. link 36 Lashley PM, Ramesh J, Ferdinand S. Spontaneous rupture of the spleen. The West Indian medical journal 1998. link 37 Tzivras M, Souyioultzis S, Tsirantonaki M, Archimandritis A. Chronic granulocytic leukemia in a patient with ankylosing spondylitis and ulcerative colitis: an interesting association. Journal of clinical gastroenterology 1997. link 38 Cohen PR. The use of gemfibrozil in a patient with chronic myelogenous leukemia to successfully manage retinoid-induced hypertriglyceridemia. The Clinical investigator 1993. link 39 Dutta TK, James J, Baruah MC, Ratnakar C. Blastomycosis-like pyoderma in a case of chronic myeloid leukaemia. Postgraduate medical journal 1992. link 40 De Keyser F, Verhoef GE, Dewyspelaere J, Boogaerts MA. Pyoderma gangrenosum in a patient with chronic myeloid leukemia. Acta clinica Belgica 1990. link 41 Kalra OP, Kalra N, Aggarwal HK, Chopra JS, Yadav MS. Chronic granulocytic leukaemia presenting with mandibular mass. The Journal of the Association of Physicians of India 1990. link 42 Varma N, Dash S, Sarode R, Bambery P. Erythroleukaemic blast crisis in chronic granulocytic leukaemia. The Journal of the Association of Physicians of India 1989. link 43 Attar E, Prokocimer M, Januszewicz E, Theodor E. Hypercalcemia complicating myelomonoblastic transformation of chronic myeloid leukemia. Acta haematologica 1988. link 44 Nolan TE, Ross WB, Caldwell C. Chronic granulocytic leukemia in pregnancy. A case report. The Journal of reproductive medicine 1988. link 45 Mackinnon S, Goldman JM. Bone marrow transplantation for patients with chronic myeloid leukaemia. British journal of hospital medicine 1988. link 46 Ng CS, Lam TK, Chan JK, Hui PK, Ng HK, Szeto SC et al.. Juvenile chronic myeloid leukemia. A malignancy of S-100 protein-positive histiocytes. American journal of clinical pathology 1988. link 47 Schallier D, Impens N, Warson F, Van Belle S, De Wasch G. Additive pulmonary toxicity with melphalan and busulfan therapy. Chest 1983. link 48 Dodsworth H, Gabriel R. Chronic granulocytic leukaemia in a patient with chronic renal failure on dialysis. Journal of clinical pathology 1981. link 49 Mehta BC, Agarwal MB. Cyclic oscillations in leukocyte count in chronic myeloid leukemia. Acta haematologica 1980. link 50 Benjamin D, Djaldetti M, Mammon Z, Shaklai M, Pinkhas J. Prolonged busulfan-induced remissions in chronic myeloid leukemia. Acta haematologica 1979. link 51 Stryckmans P, Ronge-Collard E, Debusscher L, Peyer A. Usefulness of cell kinetics for staging of chronic myeloid leukemia?. Bollettino dell'Istituto sieroterapico milanese 1978. link 52 Barr RD, Watt J. Preliminary evidence for the common origin of a lympho-myeloid complex in man. Acta haematologica 1978. link 53 Watt JL, Hamilton PJ, Page BM. Variation in the Philadelphia chromosome. Human genetics 1977. link 54 Folan DW. Severe reaction to hydroxyurea. Cutis 1977. link

Chronic myeloid leukemia